Intercure Ltd
INCR
Company Profile
Business description
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Contact
85 Medinat ha-Yehudim Street
Herzliya4676670
ISRT: +972 774605012
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
320
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.10 | 40.60 | -0.44% |
| CAC 40 | 8,167.73 | 63.89 | 0.79% |
| DAX 40 | 24,205.36 | 414.71 | 1.74% |
| Dow JONES (US) | 48,783.24 | 281.97 | 0.58% |
| FTSE 100 | 10,567.65 | 83.52 | 0.80% |
| HKSE | 25,249.48 | 518.60 | -2.01% |
| NASDAQ | 22,880.39 | 363.70 | 1.62% |
| Nikkei 225 | 54,245.54 | 2,033.51 | -3.61% |
| NZX 50 Index | 13,531.12 | 125.53 | -0.92% |
| S&P 500 | 6,882.54 | 65.91 | 0.97% |
| S&P/ASX 200 | 8,901.20 | 35.80 | -0.40% |
| SSE Composite Index | 4,082.47 | 40.20 | -0.98% |